Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ClinicalTrials.gov ID: NCT00429091

Public ClinicalTrials.gov record NCT00429091. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study identification

NCT ID
NCT00429091
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Abbott
Industry
Enrollment
243 participants

Conditions and interventions

Interventions

  • ABT-894 Drug
  • atomoxetine Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2006
Primary completion
Jul 31, 2007
Completion
Not listed
Last update posted
Nov 1, 2010

Started 2007

United States locations

U.S. sites
22
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
Site Reference ID/Investigator# 5965 San Francisco California 94143-0984
Site Reference ID/Investigator# 5955 Wildomar California 92595
Site Reference ID/Investigator# 5974 Orlando Florida 32806
Site Reference ID/Investigator# 5956 West Palm Beach Florida 33407
Site Reference ID/Investigator# 5973 Libertyville Illinois 60048
Site Reference ID/Investigator# 5968 Overland Park Kansas 66212
Site Reference ID/Investigator# 5952 Rockville Maryland 20852
Site Reference ID/Investigator# 5962 Boston Massachusetts 02114
Site Reference ID/Investigator# 5954 Okemos Michigan 48864
Site Reference ID/Investigator# 5970 Troy Michigan 48085
Site Reference ID/Investigator# 5960 Clementon New Jersey 08021
Site Reference ID/Investigator# 5963 Charlotte North Carolina 28211
Site Reference ID/Investigator# 5975 Eugene Oregon 97401
Site Reference ID/Investigator# 5971 Philadelphia Pennsylvania 19149
Site Reference ID/Investigator# 5957 Charleston South Carolina 29407
Site Reference ID/Investigator# 5972 Austin Texas 78756
Site Reference ID/Investigator# 5959 Bellaire Texas 77401
Site Reference ID/Investigator# 5969 San Antonio Texas 78258
Site Reference ID/Investigator# 5951 Salt Lake City Utah 84107
Site Reference ID/Investigator# 5964 Burlington Vermont 05401
Site Reference ID/Investigator# 5953 Virginia Beach Virginia 23452
Site Reference ID/Investigator# 5958 Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00429091, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2010 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00429091 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →